{{Rsnum
|rsid=2431260
|Gene=ESR1
|Chromosome=6
|position=151871196
|Orientation=minus
|GMAF=0.3163
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=ESR1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 6.2 | 43.8 | 50.0
| HCB | 23.5 | 54.5 | 22.0
| JPT | 30.6 | 53.2 | 16.2
| YRI | 0.0 | 6.8 | 93.2
| ASW | 1.8 | 22.8 | 75.4
| CHB | 23.5 | 54.5 | 22.0
| CHD | 27.5 | 50.5 | 22.0
| GIH | 15.3 | 42.9 | 41.8
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.7 | 31.1 | 68.2
| TSI | 15.5 | 21.6 | 62.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2431260
|Name_s=ESR1:rs2431260
|Gene_s=ESR1
|Feature=
|Evidence=PubMed ID:17327435; PubMed ID:17513703
|Annotation=Associated with type 2 diabetes and body mass index.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161145060
}}

{{PMID Auto
|PMID=18053221
|Title=Impact of estrogen receptor gene polymorphisms and mRNA levels on obesity and lipolysis--a cohort study.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2431260
|overall_frequency_n=91
|overall_frequency_d=126
|overall_frequency=0.722222
|n_genomes=49
|n_genomes_annotated=0
|n_haplomes=79
|n_articles=0
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | Affy GenomeWide 6}}